Loading company…
Oricell Therapeutics develops tumor immune cell therapies, including CAR-T products.
Founded in 2015 and based in Shanghai, Oricell Therapeutics researches and develops cell therapies for cancers including liver, ovarian, gastric and cervical cancer. Its pipeline includes autologous CAR-T products for advanced hepatocellular carcinoma and relapsed refractory multiple myeloma. In April 2026, it raised USD 110 million in Pre-IPO funding from a group of investors to advance international and multicenter clinical development and prepare for capital market milestones.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in